Moreover, levels of key AD markers (e.g., p-tau, t-tau, Aβ1-40, Aβ1-42, oligomeric Aβ) in both plasma and CSF/brain were affected by TEMT either through outright reductions or rebalancing [51]. This evidence concerns the gene MAPT and Alzheimer disease.